Quick Answer
Mereo BioPharma Group plc reported Research And Development Expense of $17.77 million for the year ending 2025.
- Mereo BioPharma Group plc showed a decrease of -15.1% in Research And Development Expense from 2024 to 2025.
- This data is from Mereo BioPharma Group plc's annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Mereo BioPharma Group plc's Research And Development Expense has declined by 48.7%.
- Historical annual values: Fiscal year 2025: $17.77 million | Fiscal year 2024: $20.93 million | Fiscal year 2023: $17.42 million | Fiscal year 2022: $29.47 million | Fiscal year 2021: $23.56 million | Fiscal year 2020: $16.35 million | Fiscal year 2019: $23.61 million | Fiscal year 2018: $22.70 million | Fiscal year 2017: $34.61 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: